ISSN: 1473-7167

Journal Home

Journal Guideline

Expert Review of Pharmacoeconomics and Outcomes Research Q2 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Review of Pharmacoeconomics and Outcomes Research is a journal indexed in SJR in Medicine (miscellaneous) and Health Policy with an H index of 61. It has a price of 2395 €. It has an SJR impact factor of 0,671 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,671.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Health Policy (Q2) Medicine (miscellaneous) (Q2) Pharmacology (medical) (Q2)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Expert Review of Pharmacoeconomics and Outcomes Research

0,671

SJR Impact factor

61

H Index

118

Total Docs (Last Year)

329

Total Docs (3 years)

5270

Total Refs

745

Total Cites (3 years)

315

Citable Docs (3 years)

1.79

Cites/Doc (2 years)

44.66

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Clinical Rheumatology Q2
Pharmacological Reports Q2
Journal of Human Nutrition and Dietetics Q2
Diseases of the Colon and Rectum Q2
Oncology Reports Q2

Compare this journals

Aims and Scope

Best articles by citations

Utility values for pre-menopausal women suffering from symptomatic uterine fibroids

Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia

Tobacco control policies and reductions in smoking rates and smoking-related deaths

Cost per quality-adjusted life year and disability-adjusted life years: the need for a new paradigm

Compliance with inhalatory therapy: an increasingly recognized clinical outcome

Update on the use of osteoarthritis-specific outcome measures

Direct and indirect cost of diabetes care among patients with type 2 diabetes in private clinics: a multicenter study in Punjab, Pakistan

Prostate cancer and QOL: impact of treatment, disease burden and psychosocial interventions

Integrated health outcomes research strategies in drug or medical device development, pre- and postmarketing: time for change

Cost-of-illness analyses for policy making: a cautionary tale of use and misuse

Management and costs of severe psoriasis: the role of new biologics

Overcoming problems with adherence to osteoporosis medication

SHOW MORE ARTICLES

Cost studies in clinical trials

Determinants of costs in blood services: blood transfusion from an economic perspective

Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (Sistema unico de Saude), Minas Gerais, Brazil

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma

Salmeterol/fluticasone combination in COPD: is together better?

Economic evaluation of noncontact normothermic wound therapy for treatment of pressure ulcers

Health-related quality of life issues in urinary urge incontinence

Pharmacoeconomics of immunoglobulins in primary immunodeficiency

Pharmacoeconomics of voriconazole in the management of invasive fungal infections

Quality of life assessment in cancer clinical research: current status and a look to the future

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?